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Background: Merkel cell carcinoma (MCC) tumor samples frequently express B-lymphoid line-
age markers. However, the reasons for expression of specific B-lymphoid lineage markers are
still unclear. We studied the expression of TdT and PAX5 (two B-cell lymphoid lineage markers)
in a large pool of MCC tissue microarray samples.
Methods: Immunoexpression and staining intensities of TdT and Pax-5 were statistically corre-
lated with patient, tumor, Merkel cell polyomavirus (MCV), and disease-specific parameters.
Results: In a cohort of 117 MCC patients and their corresponding tumor samples, TdT was
expressed in 37 (31.6%) samples and PAX5 in 26 (22.2%). Simultaneous immunostaining for TdT
and PAX5 was observed in 13 (11.1%) samples. A statistically significant relationship was
observed between MCV virus copy number and positive TdT expression (P = 0.0056). Similarly,
a significant relationship was also observed between positive TdT and tumor MCV virus positiv-
ity (P = 0.000495).
Conclusion: We observed frequent TdT and PAX5 immunoexpression in MCC tumor samples.
However, simultaneous immunoexpression of these markers was scarce. TdT expression was
statistically significantly associated with MCV positivity. The absence of a statistically significant
association between tumor parameters and disease progression markers undermines the
systemic use of these markers in clinical practice.
KEYWORDS
Merkel cell carcinoma, Merkel cell polyomavirus-lymphocyte
1 | INTRODUCTION
Merkel cell carcinoma (MCC) is a neuroendocrine carcinoma of the
skin. The cellular origins of this rare and highly aggressive skin cancer
subtype are thus far unknown. On the basis of expression patterns,
MCC tumor cells are considered to be most closely related to Merkel
cells (MC), which are mechanoreceptive cells located in the basal layer
of the epidermis. At the dermal-epidermal junction, the basal surfaces
of the MCs are closely associated with the terminal bulbs of afferent
myelinated nerve fibers. Together, the neuron and the Merkel cell are
referred to as Merkel's corpuscle, which is a sensitive mechanorecep-
tor. In the vast majority of the MCCs (approximately 80% of MCC
tumors), the DNA genome of Merkel cell polyomavirus (MCV) is inte-
grated in the tumor cell genome; this is considered as the causative
agent for tumorigenesis in MCV infection.1,2 We and others have pre-
viously shown significant morphologic and clinicopathological differ-
ences between MCV-positive and MCV-negative MCCs.2–6
Terminal deoxynucleotidyl transferase (TdT) was one of the first
DNA polymerases identified in mammals.7 DNA polymerases have a
vital role in replication, repair, and recombination of nucleic acids. To
guide each of these events, the polymerase extends a primer using a
DNA or RNA template. However, TdT possesses the unusual ability to
incorporate nucleotides without a template. TdT uses only single-
stranded DNA as the nucleic acid substrate,7 thus, synthesizing DNA
without a templating strand. Furthermore, TdT has a potential role in
the development of certain forms of leukemia. TdT is expressed in
immature, pre-B, and pre-T lymphoid cells. TdT is also used as a
marker for neoplasms of precursor B-cell and T-cell origin.8,9
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In addition to lymphoblastic neoplasms, TdT shows nuclear expression
in other small round blue cell tumors, such as medulloblastoma, Ewing
sarcoma, pediatric rhabdomyosarcoma, and small cell lung
carcinoma.10–12 Very recently, it was shown that TdT protein was
expressed in cells of epithelial origin and specifically in sebaceous
cells, both benign and malignant.13 PAX5 is one of nine mammalian
Pax transcription factors. Thus far, PAX5 is the only Pax protein
expressed within the hematopoietic system.14 PAX5 is essential for
commitment of lymphoid progenitors to the B-lymphocyte lineage14
and to MCC.15,16
Expression of B-lymphoid lineage markers in MCC is frequent
(Table 1), including TdT and PAX5. These markers are recurrent in
MCC in both primary cutaneous tumors and metastatic lymph
nodes.12,15,16,27–33 Nearly, 90% of the tumors reported express PAX5
and 65% express TdT.34 On the basis of the frequent expression of B-
lymphoid lineage markers, zur Hausen et al.31 proposed that the cell
TABLE 1 A selection of lymphocyte markers studied in Merkel cell carcinoma from 2005 to 2014
Marker Normally expressed in Study Method Samples Positive
MCV+
MCV−
TdT Pre-B and -T lymphocytes Bernd et al. (2007)17 IHC 28 10 NA
Sur et al. (2007)18 IHC 15 8 NA
Buresh et al. (2008)19 IHC 26 19 NA
Bhatia et al. (2010)20 IHC 23 5 5/17
0/6
Sidiropoulos et al. (2011)21 IHC 40 28 NA
Murakami et al. (2014)22 IHC 30 20 15/20 5/10
Kolhe et al. (2013)23 IHC 27 21 NA
Zur Hausen et al. (2013)24 IHC 16 21 15/18 1/3
PAX5 Pre-B lymphocytes Dong et al. (2005)25 IHC 31 29 20
Murakami et al. (2014)22 IHC 30 30 20/20
10/10
Kolhe et al. (2013)23 IHC 27 24 NA
Zur Hausen et al. (2013)24 IHC 21 21 18/18 3/3
Mhawech-Fauceglia et al. (2007)26 IHC 34 24 NA
Oct2 B- and T-cells, neural cells Murakami et al. (2014) IHC 30 27 16/20 9/10
IgG B lymphocytes Murakami et al. (2014) IHC 30 7 7/20 0/10
Zur Hausen et al. (2013) IHC 21 10 10/18 0/3
IgA B lymphocytes Murakami et al. (2014)22 IHC 30 7 7/20 0/10
Zur Hausen et al. (2013)24 IHC 21 10 10/18 0/3
IgM B lymphocytes Murakami et al. (2014)22 IHC 30 3 3/20 0/10
Zur Hausen et al. (2013)24 IHC 21 6 6/18 0/3
Igkappa B lymphocytes Murakami et al. (2014)22 ISH (mRNA) IHC 29 28 7 7 7/19 0/9–10
Zur Hausen et al. (2013)24 IHC 21 7 7/18 0/3
Iglambda B lymphocytes Murakami et al.(2014)22 ISH (mRNA) IHC 29 29 1 0 0–1/19 0/10
Zur Hausen et al. (2013)24 IHC 21 12 12/18 0/3
IgH-R B lymphocytes Murakami et al. (2014)22 PCR 30 20 10/201 2/10
Zur Hausen et al. (2013)24 PCR 16 16 14/14b 2/2
Igkappa — Zur Hausen et al. (2013)24 PCR 17 17 15/15c 2/2c
CD117 HSC, MPP, CMP Sur et al. (2007)18 IHC 15 8 NA
CD99 All leukocytes Sur et al. (2007)18 IHC 15 2 NA
Bhatia et al. (2010)20 IHC 23 0 —
CD10 CLP pre-B lymphocytes Sur et al. (2007)18 IHC 15 1 NA
LCA/CD45 Hematopoietic cells (exc. erythrocytes) Sur et al. (2007)18 IHC 15 0 NA
CD20 All B lymphocytes from pro-B cell phase Sur et al. (2007)18 IHC 15 0 NA
CD34 B lymphocyte precursors, myeloid blasts Sur et al. (2007)18 IHC 15 0 NA
CD3 T lymphocytes from pro-thymocytes Sur et al. (2007)18 IHC 15 0 NA
CD44 HSC, leukemic blasts, others Bhatia et al. (2010)20 IHC 19 11 11/17 3/6
CD56 Natural killer cells, activated T cells, neural cells Bhatia et al. (2010)20 IHC 23 19 14/17 5/6
CMP, common myeloid progenitor; IHC, immunohistochemistry; HSC, hematopoietic stem cell; MPP, Multipotent progenitor cells; PCR, polymerase chain
reaction; MCV Merkel cell polyomavirus; NA, not applicable.
a Monoclonal rearrangement detected in 1 MCV-positive tumor, others were polyclonal.
b Monoclonal rearrangement detected in 1 MCV-positive tumor, others were polyclonal.
c Monoclonal rearrangement detected in 3 MCV-positive tumors, others were polyclonal.
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of origin of MCC might in fact not be the post-mitotic MC, but rather
either a pro/pre-B cell or a pre-B cell. Thus, the stage of early B-cell
development in which a MCV infection occurs could determine the
phenotype and B-cell expression profile of subsequent MCC.31
We used immunohistochemistry to evaluate the frequency of
PAX5 and TdT expression in a large pool of MCC samples. We also
sought to determine whether there is an association between the
immunoexpression of PAX5 or TdT (or both) and the presence of
MCV DNA and patient and tumor characteristics. The present study
validates in a larger cohort the previous smaller scale studies on the
connection between MCC and B-lymphoid lineage markers.
2 | PATIENTS AND METHODS
The study protocol was approved by the Ethics Committee of Helsinki
University Central Hospital. The Ministry of Health and Social Affairs
granted permission to collect patient data and the National Authority
for Medicolegal Affairs to collect tissue samples.
2.1 | Patients, clinical data, and tissue samples
Data on patients diagnosed with MCC in Finland from 1979 to 2004
was obtained from the Finnish Cancer Registry and Helsinki Univer-
sity Hospital files. Clinical details were extracted from hospital
records. Formalin-fixed, paraffin-embedded tissue blocks were
retrieved from the pathology archives. MCC diagnoses were con-
firmed in a blinded fashion from our earlier studies according to well-
established criteria35 by two researchers with special expertise in
MCC pathology.
MCV detection from paraffinized tumor blocks was performed in
our previous study and is described in detail elsewhere.36 In short, the
presence of MCV DNA was analyzed from DNA extracted from repre-
sentative deparaffinized tumor sections. Quantitation of MCV DNA
was performed using real-time polymerase chain reaction (PCR). The
relative DNA sequence copy number for each tissue sample was
expressed as a ratio of MCV DNA to protein tyrosine phosphatase
gamma receptor gene DNA. The sample was considered positive
whenever MCV DNA copy number per reference gene was greater
than 0.1.37 Tissue microarray (TMA) blocks with 342 tissue cores were
used for immunohistochemistry.
2.2 | Immunohistochemistry
Five-micrometers sections were cut from TMA blocks to create three
slides from each TMA block; one was stained with hematoxylin and
eosin to create a reference slide (Figure 1) and one each was used for
immunohistochemical staining of PAX5 and TdT.
Staining for both TdT and PAX5 was performed in a BenchMark
XT (Roche Ventana, Tucson, Arizona). For TdT, the antibody used was
NCL-L-TdT-339 (clone SEN28) (Novocastra Laboratories Ltd., New-
castle, UK) at 1:50 dilution with an incubation time of 32 minutes at
room temperature. For PAX5, the antibody was 790 to 4420 (clone
SP34) “Ready to use antibody” (Roche Ventana, Tucson, Arizona); the
incubation time was 44 minutes at room temperature. The detection
kits were OptiView DAB (Roche Ventana, Tucson, Arizona) and Ultra-
View DAB with amplification kit (Roche Ventana, Tucson, Arizona). In
both cases, counterstaining was performed with Mayer's hematoxylin
(Lillie's modification) (Agilent, Santa Clara, California) (code S3309)
and the slides were cover-slipped with Sakura© Tissue-Tek Film.
2.3 | Immunostaining evaluation
TMA spots were examined and evaluated for expression of PAX5 and
TdT by light microscopy. A grading system was used for the expres-
sion of PAX5 and TdT in which the spots were classified as showing
no expression, weak positive expression, or positive expression. The
degree of immunohistochemical expression was determined by the
highest degree of expression observed. The slides were evaluated
separately by three researchers (BS, HS, and TB) in a blinded fashion.
2.4 | Morphological appearance
TMAs were evaluated by their cytomorphology to three categories;
classic, small cell variant and large cell/pleomorphic variant.
2.5 | Statistical analysis
Statistical analysis was performed with NCSS 2007 (NCSS Statistical
Software, Kaysville, Utah) software and SPSS statistics 19.0 software
(IBM Corporation, New York, New York). P-values less than 0.05 were
considered significant. Immunoexpression of TdT and PAX5 was com-
pared with gender, age, tumor location, and sun exposure pattern,
tumor laterality, disease progression, and hematological malignancy by
χ2 test. The statistical association between the presence of MCV DNA
and quantitative PCR results and immunoexpression of TdT and PAX5
were also evaluated statistically against clinical variables, virus copy
number, virus positivity by qPCR, and CM2B4 immunohistochemical
expression of MCV by Mann-Whitney analysis and Kruskal-Wallis
analysis. The cytomorphological features were analyzed statistically
against TdT, PAX5 and MCV status by χ2 test and Kruskal-Wallis
one-way ANOVA.
3 | RESULTS
3.1 | Overview of the patients
Detailed patient clinical data are shown in Table 2. Our cohort
included 117 MCC patients, of which mean age was 78 years at the
time of MCC diagnosis. Eighty-five (72%) of the patients were female.
Seven (6%) patients had been previously diagnosed with a hemato-
logic B-cell malignancy and two (1.7%) were kidney transplant recipi-
ents. The most common location for the primary tumors was the head
and neck region 65 (55%). Chronic non-shield site tumors represented
66 (56%) of all tumors. Half of the tumors (n = 58) were located on
the left side of the body. MCV tumor status was available for
113 patients, with 74% of them being MCV-positive. None of the
MCC tumors of this study were composite or collision tumors.
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3.2 | TdT and PAX5 expression in MCC
Table 3 clarifies the expression patterns of TdT and PAX5 stratified by
MCV status. In Figure 1 demonstrations of expression patterns are
shown. For TdT, we recorded positive immunostaining in 37 (31.6%)
samples. We observed strong positivity in 14 samples and weak posi-
tivity in 23 samples. Of the 37 positive TdT samples, 34 (91.8%) were
also MCV positive. We observed a statistically significant association
between virus copy number and positive TdT (P = 0.0056) in Mann-
Whitney analysis. In addition, Fisher's exact test revealed a statistically
significant association between TdT immunoexpression and MCV
virus positivity (P = 0.000495).
Altogether, 26 (22.2%) samples showed positive immunohisto-
chemistry for PAX5. Immunoexpression was strong in six samples and
weak in 20 samples. Of the 26 PAX5-positive samples, 19 (73%) were
also MCV positive.
Simultaneous immunostaining for TdT and PAX5 was observed in
13 (11.1%) samples. We observed the following three different stain-
ing patterns: weak TdT and weak PAX5 in eight samples, strong TdT
and strong PAX5 in four samples, and strong TdT and weak PAX5 in
one sample. Absent immunostaining for both TdT and PAX5 was
observed in 66 (56%) samples.
Twelve out of the 13 (92%) simultaneous TdT and PAX5 expression
samples were also MCV positive, although no statistically significant
associations were observed because of the small number of samples.
We did not observe any statistically significant associations
between TdT or PAX5 immunoexpression and demographics or disease
progression—gender, age, tumor location, and sun exposure pattern,
tumor laterality, disease progression, and hematologic malignancy.
There were 97 83% of the classic variant, 15 (13%) small cell vari-
ant and five (4%) large cell/pleomorphic variant cytomorphology in
the TMAs. In the statistical analysis, there were no correlation
between cytomorphology features and immunoexpression of TdT and
PAX5 or MCV.
4 | DISCUSSION
We studied the immunoexpression of two lymphoid lineage markers
(TdT and PAX5) from a large collection, 117 samples, of MCC tumor
material. In this study, we attempted to validate in a larger cohort the
FIGURE 1 Illustration of staining intensities in PAX5 and TdT immunohistochemistry. A, Weak positive PAX5, B, weak positive TdT,
C, positive PAX5, D, positive TdT. E and F are examples of some of the strongest staining intensities of PAX5 and TdT, respectively.
Original magnification 200×
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previous results of the connections between B-lymphoid markers and
MCC. We observed that 31.6% of the 117 MCC samples were positive
for TdT (clone SEN28) immunohistochemistry and 22.2% were positive
for PAX5 (clone SP34) immunohistochemistry. The results of the pre-
sent study are quite different from those previously reported.12,31
Regarding PAX5, in the previous studies, overall PAX5 expression
is detected in 89.5% of 143 MCC samples.34 All the samples tested by
zur Hausen et al. and Murakami et al. in two separate studies were
PAX5 positive31,32 and in the low end of expression, Mhawech-
Fauceglia et al. reported 70% expression of PAX5 in 24/34 MCC sam-
ples.27 Thus, our PAX5 positivity is judged low. To derive the reason
for the disagreement, we looked at the antibody clones used in those
studies. Zur Hausen and Murakami used the same antibody clone—
Dako; clone: DAK-Pax5—with parallel 100% PAX5 expression
rates,31,32 further Dong et al. and Mhawech-Fauceglia et al. studies
employed the same antibody clone — clone 24, BD Biosciences16,27
with 93% and 70% positivity, respectively. Hence, at least part of the
expression is dependent on the primary antibody used. Obviously, we
acknowledge the limitation of using TMA cores in this study, which
may have influenced the results. On the other hand, PAX5 expression
is typically uniform, with only very few cases showing focal expres-
sion.16 Considering the TdT expression, previous meta-analysis estab-
lished 65%, 122/187, expression in MCC,34 ranging from 21%38 to
76%.31 Our current expression rate of 32%, falls nicely in this range.
Simultaneous expression of both markers in the present study was
scarce and observed only in 11.1% of the samples. Previously, all of the
21 MCC samples that zur Hausen et al. analyzed, showed co-expression
of PAX5 and TdT in 72.8% of the samples. These seemingly contradic-
tory findings suggest the possibility that the high rates of PAX5 and TdT
expression might be partly explained by chance, given the relatively low
number of MCCs studied or antibody clone used. Of note, we observed
that PAX5 and TdT expression evaluation in MCC was occasionally con-
founded by the strong expression of these proteins by tumor-infiltrating
leukocytes. Expression of TdT, PAX5, or their simultaneous expression
did not correlate statistically significantly with patient or disease
parameters — gender, age, tumor location, and sun exposure pattern,
tumor laterality, disease progression, or hematologic malignancy.
Corroborating the zur Hausen theory, we observed a strong sta-
tistically significant association between virus copy number and TdT
expression (P = 0.0056) and between MCV positivity and TdT expres-
sion (P = 0.000495). Previously, Bhatia et al. found a similar relation-
ship between TdT immunohistochemical staining and MCV viral
abundance (P = 0.003).38 In about 80% of MCC tumors,2 oncogenesis
is initiated by MCV infection in the cell of origin.1 For MCV to initiate
MCC tumorigenesis a series of specific mutations are required39;
without these crucial mutations MCV is just a passenger virus. In the
present study, the threshold of viral copy numbers determining MCV
positivity was set at 0.1, which correlated well with LTA expression
with the mouse monoclonal antibody CM2B4. This protocol is gener-
ally accepted and widely used.2,38,40 In our 21 samples that were clas-
sified as MCV negative because of threshold, only one was weakly
positive for TdT and three for PAX5, thus, further corroborating the
finding of the relationship between TdT and MCV.
TABLE 2 Clinicopathological features of patients
N 117 (%)
Sex
Male 32 (27)
Female 85 (73)
Age Range 27-100
≤50 years 3 (2.5)
51-69 years 19 (17)
70-84 59 (50)
85-100 36 (22)
Imunocompromised state (hematologic malignancy)
NHL 2 (1.7)
CLL 5 (4.3)
Organ transplant
Kidney 2 (1.7)
Tumor location
Head and neck 65 (56)
Torso anterior 5 (4)
Torso posterior 10 (8)
Upper extremities 22 (18)
Lower extremities 15 (12)
Tumor laterality
Left 58 (50)
Right 52 (45)
Midline 1 (0.9)
Not available 6 (5.1)
Disease progression
Metastasis 41 (35)
MCV status (N = 113)
Negative 29 (26)
Positive 84 (74)
Not available 4 (3,4)
CLL, Chronic Lymphocytic Leukemia; MCV, Merkel cell polyomavirus;
NHL, Non-Hodgkin lymphoma.
TABLE 3 Representation of TdT and PAX5 expression patterns stratified by Merkel cell polyomavirus status by PCR, Merkel cell polyomavirus
status was available for 113 (96.6%) of the 117 samples
MCV
status
Expression pattern
TdT PAX5 Simultaneous TdT and PAX5
Negative,
n = 80
Positive,
n = 37
Negative,
n = 91
Positive,
n = 26
Both positive,
n = 13
Strong TdT and strong
PAX5, n = 4
Weak TdT and
weak PAX5, n = 8
Strong TdT and
weak PAX5, n = 1
MCV+ 50 34 65 19 12 4 8 1
MCV− 27 2 25 4 1 NA NA NA
Abbreviations: MCV, Merkel cell polyomavirus; NA, Not applicable.
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MCC was first described in 1972 by Dr. Cyril Toker as “trabecular
carcinoma”41 and was soon recognized as a potential mimicker of
malignant lymphoma.42 The resemblance of these two malignancies is
related to clinical and microscopic appearances.42,43 The immunohis-
tochemical profile of MCC tumors is somewhat puzzling. The histol-
ogy of MCC is typical of small round blue cell tumors, an entity that
includes a wide variety of the following highly malignant tumors: the
Ewing family of tumors, olfactory neuroblastoma, rhabdomyosarcoma,
neuroblastoma, lymphoma, desmoplastic small cell tumor, osteosar-
coma, small cell lung carcinoma, small cell melanoma, and mesenchy-
mal chondrosarcoma.44,45 Apart from lymphoblastic neoplasms, TdT is
expressed in other small round blue cell tumors.46 In particular,
another neuroendocrine carcinoma, small cell lung carcinoma, fre-
quently shows high TdT expression.12 Expression of PAX5 in cells
other than B lymphocytes has rarely been reported. In small round
blue cell tumors, PAX5 is mainly seen in MCC and small cell lung carci-
noma.16,32 Expression of PAX5 has also been observed in certain
types of poorly differentiated neuroendocrine carcinomas of the gas-
trointestinal and pancreatobiliary tracts.47 However, the expression of
PAX5 in MCC has been considered merely a reflection of cancer-
associated dysregulation of protein expression than as an indication
of lymphocytic origin of MCC.32
The immunophenotypic features of MCC are typical of neuroendo-
crine carcinomas in other sites. Thus, MCC tumors express low-molecu-
lar-weight cytokeratins.48,49 Cytokeratin-20 is the most important and
is employed in differential diagnostics, appearing in a dot-like pat-
tern.50,51 Because of its neuroendocrine differentiation, MCC always
stains positively for neuron-specific enolase, a general marker of neuro-
endocrine tumors.52,53 Other frequently expressed neuroendocrine
markers include chromogranin-A,54–56 synaptophysin,56,57 and
microtubule-associated protein.56,58 With regard to lymphoproliferative
markers, CD45 is consistently negative in MCC tumors, along with
vimentin, CD5, and CD20.59,60 Three additional lymphoproliferative
markers are nonetheless expressed in a significant proportion of MCCs,
namely PAX5, CD99, and TdT.42 However, recent research has
revealed that the immunohistochemical features of MCC are to some
extent different in MCV-positive and MCV-negative tumors.61 Immu-
noglobulin expression seems to be restricted to MCV-positive
tumors31,32 and has been postulated to be induced by MCV infection.32
To conclude, we observed frequent TdT and PAX5 immunoexpres-
sion in MCC tumor samples. However, concomitant immunoexpression
of these markers was scarce. TdT expression was statistically significantly
associated with MCV positivity. The absence of a statistically significant
association between tumor parameters and disease progression markers
undermines the systemic use of these markers in clinical practice.
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